Aldeyra Therapeutics (ALDX)

• Market cap: $158M
• 1 day: -1.49%
• 5 days: 8.61%
• 1 month: -53.91%
• 3 months: -50.93%
• 6 months: -50.37%
• Year to date: -49.23%
• 1 year: -32.74%
• 5 years: -15.87%
• 10 years: -71.93%
• Sector: Healthcare
• Industry: Biotechnology

About: Aldeyra Therapeutics Inc is a biotechnology company engaged in developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated and metabolic diseases. The company's product candidate, Reproxalap, is a treatment in late-stage development for dry eye disease and allergic conjunctivitis. In addition, it also has additional product candidates in development for proliferative vitreoretinopathy, primary vitreoretinal lymphoma and other retinal diseases, autoimmune disease, and cancer. Company products includes ADX248, ADX743, ADX631, ADX246, ADX629, ADX2191.

Employees: 9

Fund manager confidence

Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)

70% more repeat investments, than reductions

Existing positions increased: 39 | Existing positions reduced: 23

50% more first-time investments, than exits

New positions opened: 24 | Existing positions closed: 16

40% more call options, than puts

Call options by funds: $5.07M | Put options by funds: $3.63M

4% more funds holding

Funds holding: 112 [Q3] → 117 (+5) [Q4]

0.53% more ownership

Funds ownership: 61.76% [Q3] → 62.29% (+0.53%) [Q4]

0% more funds holding in top 10

Funds holding in top 10: 1 [Q3] → 1 (+0) [Q4]

6% less capital invested

Capital invested by funds: $196M [Q3] → $185M (-$11.3M) [Q4]

Research analyst outlook

2 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $9 240% upside
• Avg. target: $9.50 258% upside
• High target: $10 277% upside

2 analyst ratings

• positive: 2 100%
• neutral: 0 0%
• negative: 0 0%

BTIG Thomas Shrader 11% 1-year accuracy 1 / 9 met price target	240% upside $9	Buy Maintained	7 Apr 2025
HC Wainwright & Co. Matthew Caufield 25% 1-year accuracy 17 / 68 met price target	277% upside $10	Buy Reiterated	4 Apr 2025